Fig. 3From: Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trialKaplan-Meier curves showing PFS results for a patients with or without prior CT, and b patients with or without prior ET in MONALEESA-2. CI confidence interval, CT chemotherapy, ET endocrine therapy, HR hazard ratio, NR not reached, PFS progression-free survivalBack to article page